semaglutide – Medxy AI

Unraveling the Predictors of Peak Weight Loss with Semaglutide in Cardiovascular Patients: Insights from the SELECT Trial

By MedXY 09/29/2026

In the SELECT trial, baseline clinical factors poorly predicted peak body weight loss with semaglutide, highlighting the role of sex and dosage but underscoring substantial unexplained variability in patient response.

Cardiology Diabetes & Endocrinology news

Unraveling the Cardiovascular Benefits of Semaglutide: Insights from the SELECT Trial Mediation Analysis

By MedXY 09/28/2026

The SELECT trial demonstrates semaglutide's 20% reduction in major cardiovascular events in adults with obesity and cardiovascular disease. Mediation analysis reveals partial but uncertain roles of weight, inflammation, and glycemic markers, highlighting the need for further mechanistic research.

Diabetes & Endocrinology news

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling

By MedXY 09/23/2026

This study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production suppression.

Clinical Updates Diabetes & Endocrinology news

Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc Analysis

By MedXY 09/21/2026

Semaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.

Diabetes & Endocrinology Gastroenterology news

Comparative Impacts of Semaglutide and Bariatric Surgery on Hepatic Steatosis and Fibrosis in Obese Patients with MASLD

By MedXY 08/30/2026

This prospective cohort study compares semaglutide, bariatric surgery, and lifestyle therapy in obese patients with MASLD, demonstrating semaglutide and surgery improve liver steatosis and fibrosis markers better than lifestyle changes alone, with semaglutide showing weight-independent benefits.

Diabetes & Endocrinology news

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial

By MedXY 08/26/2026

This phase 2b trial evaluates bofanglutide's efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.

Cardiology Diabetes & Endocrinology news

Semaglutide’s Impact on Inflammation and Cardiovascular Risk in Overweight Patients: Insights from the SELECT Trial

By MedXY 08/21/2026

In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possible mechanism behind cardiovascular benefits.

Clinical Updates Diabetes & Endocrinology news

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

By MedXY 08/15/2026

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by complementary phase 3 studies on insulin icodec.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women

By MedXY 08/14/2026

This study investigates how semaglutide exposure before and during pregnancy affects gestational weight gain and key pregnancy outcomes in women with overweight or obesity, highlighting increased risks that may stem from treatment discontinuation rather than intrauterine exposure.

Clinical Updates Diabetes & Endocrinology news

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

By MedXY 08/11/2026

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.

Diabetes & Endocrinology news

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

By MedXY 06/27/2026

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in those with preserved β-cell function.

Diabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY 06/20/2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.

Diabetes & Endocrinology news Ophthalmology

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

By MedXY 06/10/2026

In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.

Diabetes & Endocrinology news

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes

By MedXY 06/10/2026

REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.

Clinical Updates news

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy

By MedXY 06/09/2026

REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.

Diabetes & Endocrinology news Ophthalmology

No Signal for Increased Neovascular AMD Risk With Semaglutide in Adults With Type 2 Diabetes: Interpretation of a Large OHDSI Network Study

By MedXY 06/04/2026

A multinational OHDSI network analysis found no meaningful association between semaglutide use and neovascular age-related macular degeneration among adults with type 2 diabetes across cohort and self-controlled designs.

Diabetes & Endocrinology news Psychiatry

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

By MedXY 05/26/2026

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antipsychotics.

Diabetes & Endocrinology news

Six-Week Native GIP Infusion Does Not Improve Glycaemic Control in Type 2 Diabetes, Alone or With Semaglutide

By MedXY 05/26/2026

A six-week native GIP infusion did not improve glucose control in type 2 diabetes, either alone or added to semaglutide, despite raising circulating GIP levels.

news Ophthalmology

GLP-1 Weight-Loss and Diabetes Drugs: What Eye Specialists Say About NAION Risk

By MedXY 05/18/2026

A new consensus statement advises cautious, shared decision-making about GLP-1 receptor agonists and NAION risk, noting that current evidence is observational, conflicting, and suggests any absolute risk increase is small.

Diabetes & Endocrinology news Psychiatry

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

By MedXY 05/05/2026

In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dysfunction.